Skip to main content
SpringerLink
Log in

Historical Perspective on the Introduction and Use of Chemotherapy for the Treatment of Osteosarcoma

  • Chapter
  • First Online:
Current Advances in Osteosarcoma

Part of the book series: Advances in Experimental Medicine and Biology ((AEMB,volume 804))

Abstract

Chemotherapy for treatment of osteosarcoma was demonstrated to be effective in eradicating primary tumor and pulmonary metastases in the mid-twentieth century. The first agents that held promise were doxorubicin and high-dose methotrexate with leucovorin (citrovorin factor) in the mid-1970s. Since then, other agents that can eliminate or cause regression of tumor have been discovered: cis-diamminedichloroplatinum II (cisplatin) and the oxazaphosphorines ifosfamide and cyclophosphamide. Additional agents await further study to define their potential. The effective agents have been utilized in various combination regimens and have escalated the survival rate from <10 to 75 %. They have also enabled pulmonary metastectomy in patients with persistent and/or recurrent pulmonary metastases and tumor ablation and limb salvage in 80 % of newly diagnosed patients. Unfortunately, however, despite these impressive advances no change in survival expectancy of patients with osteosarcoma during the past 40 years has occurred. There have been no new chemotherapeutic agents effective in addressing disease that is resistant to current agents; the few that have been introduced await further study to substantiate their efficacy. This also includes attempts at alternate administration of chemotherapy (intra-arterial and inhalation therapy.) In this chapter, we provide an account of the sequential introduction of the chemotherapeutic agents, review the results of their application in selected regimens, and discuss the role of neoadjuvant chemotherapy.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 129.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 169.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Gross SW (1879) Sarcomas of the long bones: based on a study of one hundred and sixty five cases. Am J Med Sci 8:338–377

    Article  Google Scholar 

  2. Jaffe N, Frei E III, Traggis D et al (1974) Adjuvant methotrexate and citrovorin factor in osteogenic sarcoma. N Engl J Med 291:994–997

    Article  PubMed  CAS  Google Scholar 

  3. Jeffree GM, Price CH, Sissons HA (1975) The metastatic patterns of osteosarcoma. Br M Cancer 32(1):87–107

    Article  CAS  Google Scholar 

  4. Friedman M, Carter SK (1972) The therapy of osteogenic sarcoma: current status and thoughts for the future. J Surg Oncol 4(5):482–510

    Article  PubMed  CAS  Google Scholar 

  5. Sullivan MP, Sutow WW, Taylor G (1963) L-phenylalanine mustard as treatment for metastatic osteogenic sarcoma in children. J Ped 63:227–237

    Article  CAS  Google Scholar 

  6. Sutow WW, Sullivan MP, Fernbach DJ et al (1975) Adjuvant chemotherapy in primary treatment of osteogenic sarcoma. Cancer 36:1598–1602

    Article  PubMed  CAS  Google Scholar 

  7. Evans AE (1961) Mitomycin C. Cancer Chemother Rep 14:1–9

    PubMed  CAS  Google Scholar 

  8. Frank W, Osterberg A (1971) Mitomycin C” (NSC-26980) clinical brochure. Cancer Chemother Rep 55:285–291

    Google Scholar 

  9. Finkelstein JZ, Hittle RE, Hammond CD (1969) Evaluation of a high dose cyclophosphamide regimen in childhood tumors. Cancer 23:1239–1242

    Article  Google Scholar 

  10. Haggard M (1967) Cyclophosphamide (NSC-26271) in the treatment of children with malignant neoplasms. Cancer Chemother Rep 51:403–405

    Google Scholar 

  11. Pinkle D (1962) Cyclophosphamide in children with cancer. Cancer 15:42–49

    Article  Google Scholar 

  12. Sutow WW, Vietti TJ, Fernbach DJ et al (1971) Evaluation of chemotherapy in children with metastatic Ewing’s sarcoma and osteogenic sarcoma. Cancer Chemother Rep 55:67–81

    PubMed  CAS  Google Scholar 

  13. Selawry O, Holland J, Wolman J (1988) Effect of vincristine (NSC-67574) on malignant solid tumors in children. Cancer Chemother Rep 52:497–560

    Google Scholar 

  14. Groesbeck H, Budmore J (1963) Evaluation of 5-fluouracil (5-FU) in surgical practice. Am Surg 29:683–691

    PubMed  CAS  Google Scholar 

  15. Jaffe N, Traggis D, Enriquez C (1971) Evaluation of mitomycin C (NSC-26980), phenylalanine mustard (NSC-16210) and vincristine (NSC-67574) in the treatment of osteogenic sarcoma. Cancer Chemother Rep 55:181–191

    Google Scholar 

  16. Sutow WW (1975) Combination chemotherapy with Adriamycin (NSC-123127) in primary treatment of osteosarcoma (Part III). Cancer Chemother Rep 6:315–317

    Google Scholar 

  17. Sutow WW, Gehan EA, Dyment PC et al (1978) Multi-drug adjuvant chemotherapy in osteosarcoma: interim report of the Southwest Oncology Group Studies. Cancer Treat Rep 62(2):265–269

    PubMed  CAS  Google Scholar 

  18. Wilbur J (1974) Combination chemotherapy for rhabdomyosarcoma. Cancer Chemother Rep 58(2):281–284

    PubMed  CAS  Google Scholar 

  19. Herson J, Sutow WW, Elder K (1980) Adjuvant chemotherapy in non-metastatic osteosarcoma: a Southwest Oncology Group Study. Med Pediatr Oncol 8:343–352

    Article  PubMed  CAS  Google Scholar 

  20. Cortez EP, Holland JF, Wang JJ et al (1972) Doxorubicin in disseminated osteosarcoma. JAMA 221:1132–1137

    Article  Google Scholar 

  21. Bonnaonna G, Monifardi S, Douglass RC et al (1970) Phase I and preliminary phase II evaluation of Adriamycin (NSC-123127). Cancer Res 30:2572–2582

    Google Scholar 

  22. Cortez EP, Holland JF, Wang JJ et al (1972) Chemotherapy of adjuvant osteosarcoma. In: Proceedings of the 24th Symposium of the Colston Research Society, April, 1972. Butterworths, London

    Google Scholar 

  23. Gottlieb JA, Baker LH, O’Bryan RM et al (1975) Adriamycin (NSC-123127) used alone and in combination with soft tissue bone sarcoma. Cancer Chemother Rep 3:271–282

    Google Scholar 

  24. Middleman E, Luce L, Frei E (1971) Clinical trials with Adriamycin. Cancer 28:844–850

    Article  PubMed  CAS  Google Scholar 

  25. O’Bryan RM, Luce JK, Talley R et al (1973) Phase II evaluation of Adriamycin in human neoplasia. Cancer 32:1–7

    Article  PubMed  Google Scholar 

  26. Cortez EP, Holland JF, Wang JJ et al (1974) Amputation and Adriamycin in primary osteosarcoma. N Engl J Med 291:998–1000

    Article  Google Scholar 

  27. Cassady JR, Richter MP, Piro AJ et al (1975) Radiation Adriamycin interactions-preliminary clinical observations. Cancer 36:946–949

    Article  PubMed  CAS  Google Scholar 

  28. Eilber FR, Grant T, Morton DC (1978) Adjuvant chemotherapy for osteosarcoma. Cancer Treat Rep 62:213–216

    PubMed  CAS  Google Scholar 

  29. Seifert CF, Nesser ME, Thompson DF (1994) Dexrazoxane in the prevention of doxorubicin-induced cardiotoxicity. Ann Pharmacother 28:1063–1072

    PubMed  CAS  Google Scholar 

  30. Smith MA, Ungerleider RS, Horowitz ME et al (1991) Influence of doxorubicin dose intensity on response and outcome for patients with osteogenic sarcoma and Ewing’s sarcoma. J Nat Cancer Inst 83:1460–1470

    Article  PubMed  CAS  Google Scholar 

  31. Farber S, Diamond LK, Mercer RD et al (1946) Temporary remissions in children in acute leukemia produced by folic acid antagonist 4-aminopteroyl-glutamic acid (aminopterin). N Engl J Med 238:787–793

    Article  Google Scholar 

  32. Fyfe MJ, Goldman ID (1973) Characteristics of the vincristine augmentation of methotrexate uptake in Ehrlich ascites tumor cells. J Biol Chem 248:5067–5073

    PubMed  CAS  Google Scholar 

  33. Goldin A, Mantel N, Greenhouse SW et al (1954) Effect of delayed administration of citrovorum factor on the antileukemic effectiveness of aminopterin in mice. Cancer Res 14:43–48

    PubMed  CAS  Google Scholar 

  34. Djerassi I, Abir E, Boyer GL et al (1966) Long-term remissions in childhood acute leukemia: use of infrequent infusions of methotrexate; supportive roles of platelet transfusions and citrovorum factor. Clin Pediatr 5:502–509

    Article  Google Scholar 

  35. Jaffe N (1972) Recent advances in the chemotherapy of osteogenic sarcoma. Cancer 30:1627–1631

    Article  PubMed  CAS  Google Scholar 

  36. Skipper HE, Schabel FM, Wilcox WS (1964) Experimental evaluation of potential anticancer agents. XIV Further study of certain basic concepts underlying chemotherapy of leukemia. Cancer Chemother Rep 35:1–28

    PubMed  CAS  Google Scholar 

  37. Laster WR Jr, Mayo JG, Simpson-Herrin L et al (1969) Success and failure in the treatment of solid tumors. II. Kinetic parameters and “cell cure” of moderately advanced carcinoma. Cancer Chemother Rep 53:169–188

    PubMed  CAS  Google Scholar 

  38. Schabel FM Jr (1975) Concepts for systemic treatment of micro-metastases. Cancer 35:15–24

    Article  PubMed  CAS  Google Scholar 

  39. Jaffe N (1974) Progress report on high-dose methotrexate (NSC-740) with citrovorum rescue in the treatment of metastatic bone tumor. Cancer Chemother Rep 58:275–280

    PubMed  CAS  Google Scholar 

  40. Jaffe N, Traggis D (1975) Toxicity of high-dose methotrexate (NSC-740) and citrovorum factor (NSC-3590) in osteogenic sarcoma. Cancer Chemother Rep 6:31–36

    Google Scholar 

  41. Jaffe N, Traggis D, Cassady JR et al (1976) Multidisciplinary treatment for macrometastatic osteogenic sarcoma. Br Med J 2:1039–1041

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  42. Frei E III, Jaffe N, Tattersall MHN, Pitman S, Parker L (1975) New approaches to cancer chemotherapy with methotrexate. N Engl J Med 292:846–851

    Article  PubMed  Google Scholar 

  43. Pratt C, Shanks E, Hustu O et al (1977) Adjuvant multiple drug chemotherapy for osteosarcoma of the extremity. Cancer 39:51–57

    Article  PubMed  CAS  Google Scholar 

  44. Rosen G, Tefft M, Martinez A et al (1975) Combination chemotherapy and radiation therapy in the treatment of metastatic osteosarcoma. Cancer 35:622–630

    Article  PubMed  CAS  Google Scholar 

  45. Muggia FM, Louis AC (1978) Five years of adjuvant chemotherapy: more questions than answers. Cancer Treat Rep 62:30–36

    Google Scholar 

  46. Taylor WF, Ivins JC, Prichard DJ et al (1985) Trends and variability in survival among patients with osteosarcoma: a 7-year update. Mayo Clin Proc 60(2):91–104

    Article  PubMed  CAS  Google Scholar 

  47. Edmonson JH, Green SJ, Ivins JC et al (1984) A controlled pilot study of high-dose methotrexate as postsurgical adjuvant treatment for primary osteosarcoma. J Clin Oncol 2:152–156

    PubMed  CAS  Google Scholar 

  48. Carter SK (1984) Adjuvant chemotherapy in osteogenic sarcoma: the triumph that isn’t? J Clin Oncol 2:147–148

    PubMed  CAS  Google Scholar 

  49. Gehan EA, Sutow WW, Urube Botero T et al (1978) Osteosarcoma. The MD Anderson Experience 1850-1974. In: Terry WD, Windhorst D (eds) Immunotherapy of cancer. Present status of trials in man. Raven, New York, NY, pp 271–282

    Google Scholar 

  50. Mike V, Marcove RC (1978) Osteogenic sarcoma under the age of 21. Experiences at Memorial Sloan Kettering Cancer Center. In: Terry WD, Windhorst D (eds) Immunotherapy of cancer. Present status of trials in man. Raven, New York, NY, pp 283–292

    Google Scholar 

  51. Frei E III, Blum R, Jaffe N (1978) Sarcoma: natural history and treatment. In: Terry WD, Windhorst D (eds) Immunotherapy of cancer. Present status of trials in man. Raven, New York, NY, pp 248–255

    Google Scholar 

  52. Campanacci M, Bacci G, Bertoni F et al (1981) The treatment of osteosarcoma of the extremities: twenty years’ experience at the Instituto Ortopedico Rizzoli. Cancer 48:1569–1581

    Article  PubMed  CAS  Google Scholar 

  53. Link MP, Vietti TJ (1983) Role of adjuvant chemotherapy in the treatment of osteosarcoma. Cancer Treat Rep 67:744–745

    Google Scholar 

  54. Lang EB, Levin AS (1982) Is it ethical not to conduct a prospectively controlled trial of adjuvant chemotherapy in osteosarcoma? Cancer Treat Rep 66:1699–1704

    Google Scholar 

  55. Link MP, Goorin AM, Miser A et al (1986) The effect of adjuvant chemotherapy on relapse-free survival in patients with osteosarcoma of the extremity. N Engl J Med 314:1600–1606

    Article  PubMed  CAS  Google Scholar 

  56. Eilber FR, Douglass HI Jr, Mendel ER et al (1986) Adjuvant Adriamycin and cisplatin in newly diagnosed nonmetastatic osteosarcoma of the extremity. J Clin Oncol 4:353–362

    Google Scholar 

  57. Jaffe N (1986) Osteosarcoma. N Engl J Med 314:1513

    Google Scholar 

  58. Holland JF (1987) Adjuvant chemotherapy of osteosarcoma: no runs, no hits, two men left on base. J Clin Oncol 5:4–6

    PubMed  CAS  Google Scholar 

  59. Jaffe N, Gorlick R (2008) High-dose methotrexate in osteosarcoma: let the questions surcease—time for final acceptance. J Clin Oncol 24:4365–4366

    Article  CAS  Google Scholar 

  60. Van Dalen EC, van As JW, de Camargo B Methotrexate for high-grade osteosarcoma in children and young adults. Cochrane Database of Systematic Reviews 2011, Issue 5. Art. No.: CD006325. doi: 10.1002/14651858.CD006325.pub3

  61. Jaffe N, Robertson R, Ayala A, Wallace S (1985) Comparison of intra-arterial CDP II with high-dose methotrexate and citrovorum factor rescue in the treatment of primary osteosarcoma. J Clin Oncol 3:1101–1104

    PubMed  CAS  Google Scholar 

  62. Jaffe N (1979) Antifolate rescue use of high-dose methotrexate and citrovorin factor. In: Rossowsky A (ed) Advances in chemotherapy. Marcel Decker Inc., New York, NY, pp 111–141

    Google Scholar 

  63. Rosenberg B, Van Camp L, Krigas T (1965) Inhibition of cell division in Escherichia coli by electrolysis products from a platinum electrode. Nature 205(4972):698–699

    Article  PubMed  CAS  Google Scholar 

  64. Baum E, Greenberg L, Gaynon P et al (1978) Use of cis–diamminedichloroplatinum–II (CDDP) in osteogenic sarcoma in children (Abstract C-315). Proc AACR-ASCO 19:385

    Google Scholar 

  65. Nitschke R, Starling KA, Vats T et al (1978) Cis-diamminedichloroplatinum II (NSC119875) In: Childhood malignancies. A Southwest Oncology Group study. Med Pediatr Oncol 4:127–132

    Article  PubMed  CAS  Google Scholar 

  66. Ochs JJ, Freeman AI, Douglass HO Jr et al (1978) Cis-diamminedichloroplatinum (II) in advanced osteogenic sarcoma. Cancer Treat Rep 62:239–245

    PubMed  CAS  Google Scholar 

  67. Pratt CB, Champion JE, Senzer N et al (1985) Treatment of unresectable or metastatic osteosarcoma with cisplatin or cisplatin–doxorubicin. Cancer 56:1930–1933

    Article  PubMed  CAS  Google Scholar 

  68. Jaffe N, Knapp J, Chuang VP et al (1983) Osteosarcoma intra-arterial treatment of the primary tumor with cis-diamminedichloroplatinum-II (CDP). Angiographic, pathologic and pharmacologic studies. Cancer 51:402–407

    Article  PubMed  CAS  Google Scholar 

  69. Jaffe N, Raymond AK, Ayala A et al (1989) Effect of cumulative courses of intra-arterial cis-diamminedichloroplatinum II on the primary tumor in osteosarcoma. Cancer 63:63–68

    Article  PubMed  CAS  Google Scholar 

  70. Jaffe N (2009) Osteosarcoma: review of the past, impact on the future. The American experience. In: Jaffe N, Bruland O, Bielack S (eds) Pediatric and adolescent osteosarcoma. Springer, New York, NY, pp 239–262

    Chapter  Google Scholar 

  71. Hudson M, Jaffe MR, Jaffe N et al (1990) Pediatric osteosarcoma: therapeutic strategies, results and prognostic factors derived from a 10-year experience. J Clin Oncol 8:1988–1997

    PubMed  CAS  Google Scholar 

  72. Lin PP, Patel S (2013) Osteosarcoma. In: Lin PP, Patel S (eds) Bone sarcoma. Springer, New York, NY, pp 75–97

    Chapter  Google Scholar 

  73. Petrilli AS, de Camargo B, Filho VO et al (2006) Results of the Brazilian Osteosarcoma Treatment Group Studies III and IV: prognostic factors and impact on survival. J Clin Oncol 24:1161–1168

    Article  PubMed  Google Scholar 

  74. Goodman LS, Wintrobe MM, Dameshek W et al (1946) Nitrogen mustard therapy. JAMA 132(3):126–132

    Article  CAS  Google Scholar 

  75. Sutow WW, Sullivan MP, Wilbur JR et al (1975) The study of adjuvant chemotherapy in osteogenic sarcoma. J Clin Pharmacol 15:530–533

    Article  PubMed  CAS  Google Scholar 

  76. Antman KH, Montella D, Rosenbaum C et al (1985) Phase II trial of ifosfamide with mesna in previously treated metastatic osteosarcoma. Cancer Treat Rep 69:499–504

    PubMed  CAS  Google Scholar 

  77. Bowman LG, Mayer WN, Douglass EC et al (1987) Activation of ifosfamide in metastatic and unresectable osteosarcoma (Abstract). Proc ASCO C-214:844

    Google Scholar 

  78. Meyer WH, Pratt CB, Farham D et al (1988) The activity of ifosfamide (IFOS) in previously pretreated patients with osteosarcoma (OS): preliminary results of SJCRH OS-86 Study. Proc ASCO 7:26180

    Google Scholar 

  79. Goorin AM, Harris MB, Bernstein M et al (2002) Phase II/III trial of etoposide and high–dose ifosfamide in newly diagnosed metastatic osteosarcoma: a Pediatric Oncology Group Trial. J Clin Oncol 20:426–433

    Article  PubMed  CAS  Google Scholar 

  80. Kleinerman ES, Jia S-F, Griffin J (1992) Phase II study of liposomal muramyl tripeptide in osteosarcoma: the cytokine cascade and monocyte activation following administration. J Clin Onc 10(8):1310–1316

    CAS  Google Scholar 

  81. Meyers P, Schwartz CL, Krailo M et al (2008) Osteosarcoma: the addition of muramyl tripeptide to chemotherapy improves overall survival – a report from the Children’s Oncology Group. J Clin Oncol 26:633–688

    Article  PubMed  CAS  Google Scholar 

  82. Navid F, Willert JR, McCarville MB et al (2008) Combination of gemcitabine and docetaxel in the treatment of children and young adults with refractory bone sarcoma. Cancer 113:419–425

    Article  PubMed  CAS  Google Scholar 

  83. Fox E, Aplenc R, Bagatell R (2010) A phase 1 trial and pharmacokinetic study of cediranib, an orally bioavailable pan-vascular endothelial growth factor receptor inhibitor in children and adolescents with refractory solid tumors. J Clin Oncol 28:5174–5181

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  84. Andrews NA (2013) Osteosarcoma therapy: what is the way forward? IBMS BoneKEy, doi 1038/bonekey.2013.106

    Google Scholar 

  85. Arndt CAS, Koshkina NV, Inwards CY (2010) Inhaled granulocyte macrophage colony stimulating factor for first pulmonary recurrence of osteosarcoma on disease-free survival and immunomodulation. A report from the Children’s Oncology Group. Cancer Clin Res 16:4024–4030

    Article  CAS  Google Scholar 

  86. Chou AJ, Gupta R, Bell MD et al (2013) Inhaled lipid cisplatin (ILC) in the treatment of patients with relapsed progressive osteosarcoma metastatic to the lung. Ped Blood Can 60(4):580–586

    Article  CAS  Google Scholar 

  87. Rosen G, Caparros B, Huvos AG et al (1982) Preoperative chemotherapy for osteogenic sarcoma: selection of postoperative adjuvant chemotherapy based on the response of the primary tumor to preoperative chemotherapy. Cancer 49:1221–1230

    Article  PubMed  CAS  Google Scholar 

  88. Huvos AG, Rosen G, Marcove RC (1997) Primary osteogenic sarcoma: pathologic aspects in 20 patients after treatment with chemotherapy, en bloc resection, and prosthetic bone replacement. Arch Pathol Lab Med 101:14–18

    Google Scholar 

  89. DeVita VT (1983) The relationship between tumor mass and resistance to chemotherapy. Implications for surgical adjuvant treatment of cancer. Cancer 51:1209–1220

    Article  PubMed  Google Scholar 

  90. Goldie JH, Coleman AJ (1979) A mathematical model for relating the drug sensitivity of tumors to their spontaneous mutation rate. Cancer Treat Rep 63:1727–1733

    PubMed  CAS  Google Scholar 

  91. Murray JA, Jessup K, Romsdahl M et al (1985) Limb salvage surgery in osteosarcoma: early experience at MD Anderson Hospital and Tumor Institute. Cancer Treat Symp 3:131–137

    CAS  Google Scholar 

  92. Picci P, Bacci G, Campanna R et al (1988) Neoadjuvant chemotherapy for osteosarcoma - results of a prospective study. In: Ryan JR, Baker LO (eds) Recent concepts in sarcoma treatment. Kluver Academic Publishers, Dordrecht, pp 291–295

    Chapter  Google Scholar 

  93. Picci P, Bacci G, Neff JR (1990) The influence of preoperative chemotherapy (POC) in the surgical planning in patients (PTS) with osteosarcoma (OS): a histopathological study on 205 PTS. Proc ASCO 9:310

    Google Scholar 

  94. Jaffe N, Spears R, Eftekhari F et al (1987) Pathologic fracture in osteosarcoma: effect of chemotherapy in primary tumor and survival. Cancer 59:701–709

    Article  PubMed  CAS  Google Scholar 

  95. Schabel FM Jr (1969) The use of tumor growth kinetics in planning “curative” chemotherapy of advanced solid tumors. Cancer Res 29:2384–2389

    PubMed  Google Scholar 

  96. Schabel FM (1977) Rationale for adjuvant chemotherapy. Cancer 39:2875–2882

    Article  PubMed  CAS  Google Scholar 

  97. Nachman J, Simon MA, Dean L et al (1987) Disparate histologic prognosis in simultaneously resected primary and metastatic osteosarcoma following intravenous neoadjuvant chemotherapy. J Clin Oncol 5:1185–1190

    PubMed  CAS  Google Scholar 

  98. Meyers PA, Heller G, Healy J et al (1992) Chemotherapy for non metastatic osteogenic sarcoma. The Memorial Sloan Kettering Experience. J Clin Oncol 10:5–13

    PubMed  CAS  Google Scholar 

  99. Winkler K, Beron G, Dellin G et al (1988) Neoadjuvant chemotherapy for osteosarcoma: results of a randomized cooperative trial (COSS-82) with salvage chemotherapy based on histological tumor response. J Clin Oncol 6:329–337

    PubMed  CAS  Google Scholar 

  100. Goorin AM, Schwartzentruber DJ, Devidas M et al (2003) Presurgical chemotherapy compared with immediate surgery and adjuvant chemotherapy for non metastatic osteosarcoma. Pediatric Oncology Group Study POG-8651. J Clin Oncol 21:1574–1580

    Article  PubMed  CAS  Google Scholar 

  101. Proviser AJ, Ettinger LJ, Nachman JB et al (1997) Treatment of non metastatic osteosarcoma of the extremity with preoperative and postoperative chemotherapy: a report from the Children’s Cancer Group. J Clin Oncol 15(1):1076–1084

    Google Scholar 

  102. Smeland B, Muller C, Alvegard TA et al (2003) Scandinavian Sarcoma Group Osteosarcoma Study SSG VIII: prognostic factors for outcome and the role of replacement salvage chemotherapy for poor histological responders. Eur J Cancer 30(4):488–494

    Article  Google Scholar 

  103. Benjamin RS, Chawala SP, Murray J et al (1984) Preoperative chemotherapy for osteosarcoma: a treatment approach facilitating limb salvage with major prognostic indications. In: Jones SF, Salmon SE (eds) Adjuvant therapy of cancer IV. Grune and Stratton, Philadelphia, PA, pp 601–610

    Google Scholar 

  104. Marina N, Bielack S, Whelan S et al (2009) International collaboration is feasible in trials for rare conditions: the EURAMOS experience. In: Jaffe N, Bruland O, Bielack S (eds) Pediatric and adolescent osteosarcoma. Springer, New York, NY, pp 339–353

    Chapter  Google Scholar 

  105. Bielack SS, Smeland S, Whelan J et al (2013) MAP plus maintenance pegylated interferon α-2b (MAPIfn) versus MAP alone in patients with resectable high-grade osteosarcoma and good histologic response to preoperative MAP: first results of the EURAMOS-“good response” randomization. J Clin Oncol 31 (suppl; abstr LBA10504)

    Google Scholar 

  106. Briccoli A, Rocca M, Salone M et al (2005) Resection of recurrent pulmonary metastases in patients with osteosarcoma. Cancer 104(8):1721–1725

    Article  PubMed  Google Scholar 

  107. Martini N, McCormack PM (1988) Pulmonary resection in sarcoma metastases. In: Ryan JR, Baker LO (eds) Recent concepts in sarcoma treatment. Kluwer Academic Publishers, Dordrecht, pp 197–200

    Chapter  Google Scholar 

  108. Jaffe N, Smith E, Abelson HT et al (1983) Osteogenic sarcoma: alterations in the pattern of pulmonary metastases with adjuvant chemotherapy. J Clin Oncol 1:252–254

    Google Scholar 

  109. Harting MT, Blakely ML, Jaffe N et al (2006) Long-term survival after aggressive resection of pulmonary metastases among children and adolescents with osteosarcoma. J Pediatr Surg 41(1):194–199

    Article  PubMed  Google Scholar 

  110. Phemister DB (1940) Conservative surgery in the treatment of bone tumors. Surg Gynecol Obstet 70:355–364

    Google Scholar 

  111. Parrish FF (1968) Treatment of bone tumors by total excision and replacement with massive autologous and homologous grafts. J Bone Joint Surg 48A:968–990

    Google Scholar 

  112. Jaffe N, Carrasco H, Raymond K et al (2002) Can cure in patients with osteosarcoma be achieved exclusively with chemotherapy and abrogation of surgery? Cancer 95:2202–2210

    Article  PubMed  Google Scholar 

  113. McCarten KM, Jaffe N, Kirkpatrick JA (1980) The changing radiographic appearance of osteosarcoma. Ann Radiol 23:203–208

    PubMed  CAS  Google Scholar 

  114. Bielack S, Jurgens H, Jundt G et al (2009) Osteosarcoma: the COSS experience. In: Jaffe N, Bruland O, Bielack S (eds) Pediatric and adolescent osteosarcoma. Springer, New York, NY, pp 289–308

    Chapter  Google Scholar 

  115. Myers PA, Gorlick R, Heller G et al (1998) Intensification of preoperative chemotherapy for osteogenic sarcoma: results of the Memorial Sloan Kettering (T12) protocol. J Clin Oncol 16(7):2452–2458

    Google Scholar 

  116. Ferrari S, Palmerini E, Staals EL et al (2009) The treatment of nonmetastatic high-grade osteosarcoma of the extremity: review of the Italian Rizzoli experience. Impact on the future experience. In: Jaffe N, Bruland O, Bielack S (eds) Pediatric and adolescent osteosarcoma. Springer, New York, NY, pp 275–287

    Chapter  Google Scholar 

  117. Bruland OS, Bauer H, Alvegard T et al (2009) Treatment of osteosarcoma. The Scandinavia Sarcoma Group experience. In: Jaffe N, Bruland O, Bielack S (eds) Pediatric and adolescent osteosarcoma. Springer, New York, NY, pp 309–318

    Chapter  Google Scholar 

  118. Delepine N, Delepine G, Jasmine C et al (1988) Importance of age and methotrexate dosage: prognosis in children and young adults with high-grade osteosarcoma. Biomed Pharmacother 42:257–262

    PubMed  CAS  Google Scholar 

  119. Le Deley M-C, Guinebretiere J-M, Gentet J-C (2007) A randomized trial comparing preoperative high-methotrexate plus doxorubicin to high dose methotrexate plus etoposide and ifosfamide in osteosarcoma patients. Eur J Cancer 43(4):751–761

    Article  CAS  Google Scholar 

  120. Pratt CB, Luo X, Fay L et al (1996) Response of pediatric malignant solid tumors following ifosfamide or ifosfamide/carboplatin/etoposide. A single hospital experience. Med Pediatr Oncol 27:145–148

    Article  PubMed  CAS  Google Scholar 

  121. Daw NE, Neel MD, Rao BN (2011) Frontline treatment of localized osteosarcoma without methotrexate: results of the St Jude Children’s Research Hospital OS99 trial. Cancer 117(12):2770–2778

    Article  PubMed  PubMed Central  Google Scholar 

  122. Meyer WH, Pratt CB, Poquette CA et al (2001) Carboplatin/ifosfamide window therapy for osteosarcoma: results of the St Jude Children’s Research Hospital OS-91 trial. J Clin Oncol 19:171–182

    PubMed  CAS  Google Scholar 

  123. Krailo M, Ertel I, Makley J et al (1987) A randomized study comparing high dose methotrexate with moderate dose methotrexate as components of adjuvant therapy in childhood nonmetastatic osteosarcoma: a report from the Children’s Cancer Study Group. Med Pediatr Oncol 15:69–77

    Article  PubMed  CAS  Google Scholar 

  124. Ayan I, Kebudi R, Ozger H (2009) Childhood osteosarcoma: multimodal therapy in a single-institution Turkish series. In: Jaffe N, Bruland O, Bielack S (eds) Pediatric and adolescent osteosarcoma. Springer, New York, NY, pp 319–338

    Chapter  Google Scholar 

  125. Bernthal N, Federman N, Nelson S (2012) Early pathologic response to neoadjuvant therapy predictive of long term (>25 year) survival in osteosarcoma. Paper presented at 2012 annual meeting of the Connective Tissue Oncology Society, Prague, Czech Republic, and 14–17 November 2012

    Google Scholar 

  126. Craft AW (2009) Osteosarcoma: the European Osteosarcoma Intergroup (EOI) perspective. In: Jaffe N, Rutland O, Bielack S (eds) Pediatric and adolescent osteosarcoma. Springer, New York, NY, pp 263–274

    Chapter  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Pediatrics, Children’s Cancer Hospital, University of Texas MD Anderson Cancer Center, Houston, TX, 77030, USA

    Norman Jaffe M.D., Dip., Paed, D.Sc.

Authors
  1. Norman Jaffe M.D., Dip., Paed, D.Sc.
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Norman Jaffe M.D., Dip., Paed, D.Sc. .

Editor information

Editors and Affiliations

  1. Division of Pediatrics, Department of Cancer Biology, The Mary V. and John A. Reilly Distinguished Chair, University of Texas M.D. Anderson Cancer Center, Houston, Texas, USA

    Eugenie S. Kleinerman, M.D.

Rights and permissions

Reprints and permissions

Copyright information

© 2014 Springer International Publishing Switzerland

About this chapter

Cite this chapter

Jaffe, N. (2014). Historical Perspective on the Introduction and Use of Chemotherapy for the Treatment of Osteosarcoma. In: Kleinerman, M.D., E. (eds) Current Advances in Osteosarcoma. Advances in Experimental Medicine and Biology, vol 804. Springer, Cham. https://doi.org/10.1007/978-3-319-04843-7_1

Download citation

Publish with us

Policies and ethics

Search

Navigation